Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet